2 June 2026
Thalia Therapeutics plc
("Thalia" or the "Company")
CEO Interview: Building a Differentiated RNA Therapeutics Company
Thalia Therapeutics plc (AIM: THAT), a biotechnology company developing innovative RNA therapeutics, is pleased to announce the release of a new video interview with Chief Executive Officer, Dr David Solomon, speaking with BioHub.
In the interview, Dr Solomon discusses the significant room for innovation in RNA therapeutics and how Thalia is positioning itself in this rapidly expanding market to develop differentiated next-generation RNA Therapeutics.
In particular, the discussion also explores Thalia's differentiated approach to treating cardiovascular disease, with a long-acting preclinical candidate that addresses two independent risk factors of cardiovascular disease simultaneously, PCSK9 and Lp(a), offering the potential for additive or synergistic benefits.
The interview is available to watch via the Company's website at: https://investors.thaliatx.com/activity-updates/epjN8P-thalia-tx-on-biohub
There is growing interest in genetically targeted approaches to cardiovascular disease and PCSK9-targeted therapies, as reflected in recent clinical research published in The New England Journal of Medicine here: https://www.nejm.org/doi/10.1056/NEJMoa2601283
- Ends -
For more information please contact:
|
Thalia Therapeutics plc Dr David H Solomon, Chief Executive Officer |
Via Thalia Investor Hub |
|
SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Jen Clarke (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) |
Tel: +44 (0)20 3470 0470 |
|
Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker Guy McDougall |
Tel: +44 (0)20 3657 0050 |
|
Northstar Communications Investor relations and Communications Sarah Hollins Cohesion Bureau Investor relations and Communications Mary-Ann Chang |
Tel: +44 (0)20 7183 2463 Tel: +44 (0)7483 284853 |
About Thalia Therapeutics plc
Thalia Therapeutics is a pre-clinical biotechnology company developing innovative RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease. With a growing, differentiated pipeline, de-risked by validated therapeutic targets, we aim to treat diseases at the source by silencing or modifying the genes that cause or contribute to them.
Our preclinical bispecific siRNA is a potentially long-acting treatment for atherosclerotic cardiovascular disease, which addresses two independent drivers of cardiovascular risk. Our proprietary delivery technology, Nuvec®, offers the potential to overcome the fundamental challenges of RNA delivery, enabling targeted, scalable RNA therapeutics.
For further information visit www.thaliatx.com